Eledon Pharmaceuticals Inc
ELDN3.340USD
-0.040-1.18%
Horário de mercado （ET）Cotações atrasadas em 15 min
200.01MValor de mercado
7.16P/L TTM
Mais detalhes de Eledon Pharmaceuticals Inc Empresa
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Informações da empresa
Código da empresaELDN
Nome da EmpresaEledon Pharmaceuticals Inc
Data de listagemSep 17, 2014
CEODr. David-Alexandre C. (DA) Gros, M.D.
Número de funcionários31
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 17
Endereço19800 Macarthur Blvd.
CidadeIRVINE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92612
Telefone19492388090
Sitehttps://eledon.com/
Código da empresaELDN
Data de listagemSep 17, 2014
CEODr. David-Alexandre C. (DA) Gros, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David-Alexandre C. (DA) Gros, M.D.
Dr. David-Alexandre C. (DA) Gros, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
9.00K
--
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
677.00
--
Dr. Allan D. Kirk, M.D., Ph.D.
Dr. Allan D. Kirk, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Bryan E. Smith, J.D.
Mr. Bryan E. Smith, J.D.
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. James Robinson
Mr. James Robinson
Independent Director
Independent Director
--
--
Dr. Jan Hillson, M.D.
Dr. Jan Hillson, M.D.
Independent Director
Independent Director
--
--
Dr. June Lee, M.D.
Dr. June Lee, M.D.
Independent Director
Independent Director
--
--
Dr. Steven N. Perrin, Ph.D.
Dr. Steven N. Perrin, Ph.D.
President, Chief Scientific Officer, Director
President, Chief Scientific Officer, Director
--
--
Mr. John S. McBride
Mr. John S. McBride
Independent Director
Independent Director
--
--
Mr. Paul Little
Mr. Paul Little
Chief Financial Officer
Chief Financial Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David-Alexandre C. (DA) Gros, M.D.
Dr. David-Alexandre C. (DA) Gros, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
9.00K
--
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
677.00
--
Dr. Allan D. Kirk, M.D., Ph.D.
Dr. Allan D. Kirk, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Bryan E. Smith, J.D.
Mr. Bryan E. Smith, J.D.
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. James Robinson
Mr. James Robinson
Independent Director
Independent Director
--
--
Dr. Jan Hillson, M.D.
Dr. Jan Hillson, M.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 4 de jul
Atualizado em: sex, 4 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BVF Partners L.P.
10.51%
RA Capital Management, LP
5.96%
The Vanguard Group, Inc.
5.54%
First Light Asset Management, LLC
3.89%
Sphera Funds Management Ltd.
3.85%
Other
70.25%
Investidores
Investidores
Proporção
BVF Partners L.P.
10.51%
RA Capital Management, LP
5.96%
The Vanguard Group, Inc.
5.54%
First Light Asset Management, LLC
3.89%
Sphera Funds Management Ltd.
3.85%
Other
70.25%
Tipos de investidores
Investidores
Proporção
Hedge Fund
28.61%
Investment Advisor
17.21%
Investment Advisor/Hedge Fund
10.61%
Venture Capital
5.96%
Corporation
1.36%
Research Firm
1.17%
Pension Fund
0.12%
Family Office
0.07%
Individual Investor
0.03%
Other
34.87%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
126
38.97M
65.08%
-2.26M
2025Q1
124
39.32M
65.66%
-3.87M
2024Q4
105
38.47M
64.39%
+11.26M
2024Q3
70
19.89M
51.00%
-1.66M
2024Q2
71
20.04M
55.99%
+4.61M
2024Q1
65
11.37M
47.26%
-1.53M
2023Q4
63
10.93M
50.76%
-2.06M
2023Q3
65
10.70M
50.83%
-4.12M
2023Q2
66
11.20M
53.85%
+179.31K
2023Q1
67
8.42M
61.13%
-3.83M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BVF Partners L.P.
6.29M
10.51%
--
--
Mar 31, 2025
RA Capital Management, LP
3.57M
5.96%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.95M
4.93%
+58.49K
+2.02%
Mar 31, 2025
First Light Asset Management, LLC
2.33M
3.89%
--
--
Mar 31, 2025
Sphera Funds Management Ltd.
2.31M
3.85%
-244.50K
-9.58%
Mar 31, 2025
Blue Owl Capital Holdings LP
1.82M
3.04%
-140.00K
-7.14%
Mar 31, 2025
Woodline Partners LP
1.67M
2.79%
--
--
Mar 31, 2025
Susquehanna International Group, LLP
1.59M
2.65%
+1.32M
+489.41%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
1.32M
2.2%
-196.91K
-12.99%
Mar 31, 2025
Ensign Peak Advisors, Inc.
1.26M
2.11%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0.04%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
ALPS Medical Breakthroughs ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Inspire Fidelis Multi Factor ETF
0%
Ver Mais
iShares Micro-Cap ETF
Proporção0.04%
Global X Russell 2000 ETF
Proporção0.01%
Proshares Ultra Russell 2000
Proporção0.01%
ProShares UltraPro Russell2000
Proporção0.01%
ProShares Hedge Replication ETF
Proporção0.01%
iShares Russell 2000 Value ETF
Proporção0.01%
ALPS Medical Breakthroughs ETF
Proporção0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
DFA Dimensional US Sustainability Core 1 ETF
Proporção0%
Inspire Fidelis Multi Factor ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
Data
Tipo
Proporção
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
